Drugs and patents in ATC class G04BE - Drugs used in erectile dysfunction

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ALPROSTADIL	alprostadil
CAVERJECT	alprostadil
CAVERJECT IMPULSE	alprostadil
EDEX	alprostadil
PROSTIN VR PEDIATRIC	alprostadil
MUSE	alprostadil
VYBRIQUE	sildenafil citrate
>Tradename	>Generic Name

Last updated: June 12, 2026

Market dynamics and patent landscape for ATC Class G04BE erectile dysfunction drugs: who owns the IP, when does exclusivity end, and what generic/biosimilar risks exist?

ATC Class G04BE (drugs used in erectile dysfunction) is dominated by phosphodiesterase type 5 (PDE5) inhibitors. Patent risk is concentrated in branded schedules for sildenafil, tadalafil, vardenafil, and avanafil, with most “hard” exclusivity now driven by (1) composition-of-matter patents on new salts/polymorphs and (2) formulation and method-of-use patents for specific dose forms and regimens. Market access is usually managed through generic competition at scale, with fewer late-stage patent “cliff” events than in earlier years.

What is the ATC G04BE market structure for erectile dysfunction drugs and how do patents shape pricing?

The G04BE market is largely genericized at the molecule level, but brands persist through patents on specific products: dose strengths, salts, crystalline forms, film coatings, solubilizing systems, and therapeutic use claims. The practical outcome is a split market: (1) wholesale penetration by generics for older PDE5 inhibitors and (2) brand durability for products that had better IP coverage at launch or have line-extensions with active filings and ongoing litigation.

Which drug substances dominate ATC G04BE and what are the typical revenue patterns?

Primary PDE5 inhibitors in G04BE:

Sildenafil (often as sildenafil citrate)
Tadalafil (often as tadalafil)
Vardenafil (often as vardenafil hydrochloride)
Avanafil (often as avanafil)

Revenue is typically bifurcated:

Sildenafil: significant generic penetration; brand protection largely depends on specific formulations and jurisdictional patent remnants.
Tadalafil: long commercial lifecycle and historically thicker brand support due to dosing convenience (once-daily option in many markets) and formulation IP.
Vardenafil and avanafil: smaller franchise scale than tadalafil and sildenafil, with product-level IP historically less extensive but still relevant for specific dose forms.

How do patent estates translate into commercial dynamics?

Key market mechanisms:

Paragraph IV-style competition: for US where applicable, generic manufacturers typically target product-specific Orange Book listings tied to branded formulations.
Switching costs: clinicians and pharmacies can switch among PDE5 inhibitors, but product-specific factors like dosing regimen and tolerability can slow full substitution after patent expiry.
Line extensions: new patents can delay generic competition even after core compound patents expire, usually through:
- controlled-release or fast-dissolve formats,
- polymorph/crystal form protection,
- dosing regimens (method-of-use),
- and process/manufacturing claims.

What patents protect erectile dysfunction PDE5 inhibitors like sildenafil, tadalafil, vardenafil, and avanafil?

Core compound protection for first-generation PDE5 inhibitors generally expired years ago in most major jurisdictions. Current patent landscapes for G04BE typically consist of:

Formulation patents (salt, polymorph, amorphous form, particle size distribution, film coat systems, solid dispersion, or excipient systems)
Method-of-use patents (dose regimens, patient subpopulations, or specific therapeutic steps)
Manufacturing/process patents (improved synthesis routes or crystallization processes)
Device-adjacent patents (less common in classic PDE5 tablets)

Sildenafil: where is IP usually concentrated now?

For sildenafil-based products, remaining patent protection (where it exists) typically targets:

specific polymorph/crystal forms of sildenafil citrate,
specific dose forms and coating systems that alter dissolution,
and sometimes process claims.

Commercially, sildenafil’s market share advantage in many countries stems from generic breadth and low price, limiting late-stage brand margins unless a brand holds active, enforceable listings for a specific product.

Tadalafil: what formulation and regimen IP tends to persist?

Tadalafil has historically shown stronger product-level durability, largely through:

tablet formulations with improved dissolution/handling,
and potentially method-of-use or regimen-related claims tied to daily dosing behavior (depending on jurisdiction and patent family status).

Vardenafil and avanafil: what is the usual patent “shape”?

For vardenafil and avanafil, market-level IP persistence is typically narrower than tadalafil’s. Surviving estates, when present, tend to cluster in:

formulation and solid-state properties,
process improvements,
and, less frequently, method-of-use.

When do erectile dysfunction patents lose exclusivity by drug: sildenafil vs tadalafil vs vardenafil vs avanafil?

Without a jurisdiction-specific Orange Book extract and specific branded products currently listed, providing exact expiry dates and litigation-linked exclusivity windows would be incomplete. At a market-structure level, exclusivity loss in G04BE is best understood as a sequence:

Compound patent expiry (molecule-level): broadly earlier.
Line extension expiry (formulation/polymorph/regimen): later and more variable by jurisdiction.
Regulatory exclusivities (US): limited relevance for classic PDE5 inhibitors unless there were new drug approvals under new NDAs.

Practically, the generic entry rhythm for G04BE is driven by:

whether an Orange Book listing still exists for the targeted branded product,
and whether enforceable patents cover the generic’s proposed product.

What is the Orange Book status of sildenafil, tadalafil, vardenafil, and avanafil erectile dysfunction products?

Orange Book status requires current listing-by-product data (NDA/BLA, listed patents, and certification records). Without the ability to compile live Orange Book records in this response, mapping Orange Book status to named products and listing-specific patents would risk inaccuracies.

How do Paragraph IV generic challenges work in erectile dysfunction drug launches?

In the US, generic manufacturers typically attempt to launch at the earliest date permitted by:

patent expiry of all relevant Orange Book-listed patents (for the reference listed drug), or
successful challenge via litigation (Paragraph IV) and any court-ordered or settlement-driven entry dates.

For G04BE products, the typical litigation triggers are:

composition-of-matter or formulation patents listed for the branded product,
method-of-use claims connected to a dosage regimen,
and manufacturing/process patents where the generic’s route of synthesis could still be considered infringing.

What patent litigation affects erectile dysfunction drugs and what settlement patterns dominate?

G04BE litigation tends to be product-specific rather than molecule-level. Patterns observed in PDE5 inhibitor landscapes generally include:

early-stage disputes around formulation and method-of-use claims,
settlements that may include:
- delayed entry dates for the generic,
- non-infringement commitments,
- and sometimes co-promotion or supply arrangements.

A defensible answer here requires case-level identifiers (court docket, asserted patents, settlement terms). Without case data in the input, listing specific litigations would not meet the requirement for hard, actionable details.

What formulations are protected in G04BE and what generic entry risks exist?

The most common formulation-driven barriers for generics in G04BE are:

Solid-state and dissolution control patents

polymorph/crystal form protection,
particle size and morphology control,
amorphous solid dispersion protection,
controlled release or modified dissolution profiles.

Salt and particle engineering

For each active ingredient, if a brand uses a specific salt form or engineering approach protected by active claims, a generic can be blocked unless it designs around those claims or waits for patent expiry.

Method-of-use and regimen claims

Method-of-use claims can restrict generic labeling, not just manufacturing. Even if the generic can make the tablet, the launch can be constrained if the FDA-approved label or clinical instructions infringe active use patents.

How does generics competition change after patent expiry in erectile dysfunction drugs?

Once compound and product-specific patents are cleared:

price typically drops sharply,
pharmacy formulary adoption accelerates,
and multiple manufacturers compete in multiple strengths.

Residual brand strength then depends on:

dosing convenience (e.g., daily vs as-needed schedules),
perceived tolerability,
and inertia from prescribers who have established treatment routines.

Which companies are leading erectile dysfunction drug markets and what IP strategy do they use?

At the product IP level, major rights holders generally include:

brand originators with continuing line-extension portfolios,
branded companies with formulation improvements,
and generic firms able to exploit expiry or design-around strategies once listings are cleared.

A company-by-company IP map requires named NDA-level products and associated assignees from Orange Book and global patent families. That mapping cannot be produced reliably from the prompt alone.

How strong is the patent estate for ATC G04BE erectile dysfunction drugs?

At a high level, strength is strongest in:

jurisdictions with active formulation or method-of-use families,
specific marketed dose forms still covered by last-mile line extensions,
and territories where litigation has produced continued enforceability through ongoing validity challenges.

Strength is weaker for:

molecule-level claims that have mostly aged out,
generic entry paths where design-around is straightforward (e.g., different salt form or different formulation route without equivalence constraints).

Comparative outlook: tadalafil vs sildenafil vs vardenafil vs avanafil for IP and generic risk

Generalized, market-practice comparison:

Tadalafil: often has the most persistent product-level IP influence due to stronger commercial footprint and historical line-extension focus.
Sildenafil: broad genericization reduces overall brand IP leverage; remaining barriers are usually product- and jurisdiction-specific formulation claims.
Vardenafil and avanafil: smaller brands with potentially narrower formulation portfolios, which can reduce the number of active patents influencing generic entry timing.

Exact relative risk by time-to-launch requires the active patent listing sets per reference product in each target jurisdiction.

What are the regulatory milestones for erectile dysfunction drugs that interact with patent timelines?

For PDE5 inhibitors, the regulatory milestones that matter for generic launch timing are:

FDA approval date for the reference product (drives listing),
any new supplemental approvals for dose forms or strengths (potentially new Orange Book listings),
and FDA approval of generics under ANDA with certification paragraphs tied to listed patents.

In most countries, the ability to file and the time of approval depend on both patent status and regulatory exclusivity frameworks, but PDE5 inhibitors often have limited remaining regulatory exclusivity once NDAs are fully genericized.

Key Takeaways

ATC G04BE is dominated by PDE5 inhibitors; patent relevance now comes from formulation, polymorph/solid-state, process, and method-of-use patents rather than primary compound protection.
Generic entry timing hinges on product-specific Orange Book listings and whether active patents cover the generic’s proposed formulation, dissolution profile, or label regimen.
Market dynamics favor rapid price competition once product-level listings expire, with brand durability mainly tied to dosing convenience and remaining line-extension IP in certain jurisdictions.

FAQs

Which PDE5 inhibitor has the highest likelihood of formulation-based patent barriers in erectile dysfunction?
How do method-of-use erectile dysfunction patents affect generic labeling and launch timing?
What types of solid-state changes (polymorph vs salt vs particle size) most often create generic entry design-around challenges?
How do supplemental NDA approvals for new dose strengths typically alter Orange Book patent coverage?
What settlement terms are most common in US patent litigations for PDE5 inhibitor ANDA launches?

References

International Committee of Medical Journal Editors. (ICMJE). Uniform requirements for manuscripts.
US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.

Drugs in ATC Class G04BE

Drugs in ATC Class: G04BE - Drugs used in erectile dysfunction